Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30784948 | 1.00 | GSK3B (0.56) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL27782372 | 0.86 | GSK3B (0.53) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL310054 | 0.83 | GSK3B (0.50) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL11688423 | 0.83 | GSK3B (0.50) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11688435 | 0.83 | GSK3B (0.50) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL18816698 | 0.82 | HSD17B10 (0.54) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL12084895 | 0.81 | GSK3B (0.51) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL4918506 | 0.81 | HPGD (0.61) | GSK3BHSD17B10SMN1; SMN2TSHRGRM5 | |
| SCHEMBL12989219 | 0.81 | GSK3B (0.55) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL28406191 | 0.81 | PTGDR2 (0.49) | SMN1; SMN2ALDH1A1PTGDR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657015-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-23 | — | — | US | disclosed |
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| EP-1348706-B1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | disclosed |
| EP-1784450-B1 | METHOD FOR UNDISTORTED PIGMENTATION OF PARTIALLY CRYSTALLINE PLASTICS | CLARIANT PRODUKTE DEUTSCHLAND (DE) | 2009-07-15 | — | — | EP | disclosed |
| US-7067537-B2 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1348706-A1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| EP-0132851-B1 | 5-SUBSTITUTED(1,2,4)TRIAZOLO(1,5-C)PYRIMIDIN-2-AMINES | AMERICAN CYANAMID COMPANY (US) | 1989-10-04 | — | — | EP | disclosed |
| US-4579848-A | ANTIASTHMA AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-04-01 | — | — | US | disclosed |
| EP-0132851-A1 | 5-Substituted(1,2,4)triazolo(1,5-c)pyrimidin-2-amines | AMERICAN CYANAMID COMPANY (US) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | GSK3B 2680/4885HSD17B10 2647/4885KDM4E 3396/4885 |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | CYP17A1, CYP21A2, HSD17B1 | GSK3B 1171/4885HSD17B10 22/4885KDM4E 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.